Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Entrada Therapeutics, Inc. (TRDA) since 2021 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Entrada Therapeutics, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 1689375.
Total stock buying since 2021: $37,264,646.
Total stock sales since 2021: $9,923,455.
Total stock option exercises since 2021: $431,289.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 305,784 | $2,157,443 | 11,134 | $23,381 |
| 2024 | 17,636 | $242,270 | 195,392 | $3,706,009 | 52,918 | $151,123 |
| 2023 | 0 | $0 | 132,922 | $2,105,011 | 75,500 | $158,546 |
| 2022 | 166,400 | $1,022,376 | 115,973 | $1,954,992 | 43,299 | $87,319 |
| 2021 | 1,800,000 | $36,000,000 | 0 | $0 | 5,200 | $10,920 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2025-07 | 0 | $0 | 104,000 | $761,258 | 0 | $0 |
| 2025-06 | 0 | $0 | 200,000 | $1,377,150 | 0 | $0 |
| 2025-04 | 0 | $0 | 0 | $0 | 11,134 | $23,381 |
| 2025-03 | 0 | $0 | 1,784 | $19,035 | 0 | $0 |
| 2024-12 | 0 | $0 | 110,235 | $2,252,827 | 5,000 | $10,500 |
| 2024-11 | 0 | $0 | 32,065 | $618,173 | 7,000 | $14,700 |
| 2024-10 | 0 | $0 | 600 | $10,800 | 0 | $0 |
| 2024-09 | 0 | $0 | 9,587 | $145,138 | 0 | $0 |
| 2024-08 | 0 | $0 | 27,097 | $446,531 | 20,000 | $34,800 |
| 2024-07 | 0 | $0 | 4,896 | $82,463 | 0 | $0 |
| 2024-06 | 0 | $0 | 1,000 | $16,174 | 11,918 | $72,223 |
| 2024-05 | 4,476 | $63,305 | 3,000 | $45,129 | 0 | $0 |
| 2024-04 | 2,600 | $35,289 | 0 | $0 | 0 | $0 |
| 2024-03 | 10,560 | $143,676 | 5,912 | $72,784 | 9,000 | $18,900 |
| 2024-01 | 0 | $0 | 1,000 | $15,990 | 0 | $0 |
| 2023-12 | 0 | $0 | 13,500 | $211,617 | 12,500 | $26,249 |
| 2023-11 | 0 | $0 | 1,000 | $16,230 | 0 | $0 |
| 2023-10 | 0 | $0 | 1,000 | $15,000 | 0 | $0 |
| 2023-09 | 0 | $0 | 3,814 | $53,635 | 0 | $0 |
| 2023-08 | 0 | $0 | 27,710 | $418,009 | 26,710 | $56,089 |
| 2023-07 | 0 | $0 | 34,975 | $630,191 | 10,000 | $20,999 |
| 2023-06 | 0 | $0 | 33,482 | $509,012 | 26,290 | $55,209 |
| 2023-04 | 0 | $0 | 8,053 | $136,413 | 0 | $0 |
| 2023-03 | 0 | $0 | 5,388 | $66,902 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-07-09 | Parmar Kush | Sale | 27,000 | 7.50 | 202,554 |
| 2025-07-09 | Schwab Andrew J. | Sale | 27,000 | 7.50 | 202,554 |
| 2025-07-01 | Parmar Kush | Sale | 25,000 | 7.12 | 178,075 |
| 2025-07-01 | Schwab Andrew J. | Sale | 25,000 | 7.12 | 178,075 |
| 2025-06-30 | Parmar Kush | Sale | 25,000 | 6.81 | 170,325 |
| 2025-06-30 | Schwab Andrew J. | Sale | 25,000 | 6.81 | 170,325 |
| 2025-06-27 | Parmar Kush | Sale | 75,000 | 6.91 | 518,250 |
| 2025-06-27 | Schwab Andrew J. | Sale | 75,000 | 6.91 | 518,250 |
| 2025-04-03 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 11,134 | 2.10 | 23,381 |
| 2025-03-17 | Wentworth Kory James (Chief Financial Officer) | Sale | 1,784 | 10.67 | 19,035 |
| 2024-12-11 | Mpm Bioventures 2018 Gp Llc | Sale | 21,787 | 20.23 | 440,751 |
| 2024-12-11 | Mpm Asset Management Investors Bv2018 Llc | Sale | 21,787 | 20.23 | 440,751 |
| 2024-12-10 | Mpm Bioventures 2018 Gp Llc | Sale | 22,935 | 20.77 | 476,359 |
| 2024-12-10 | Mpm Asset Management Investors Bv2018 Llc | Sale | 22,935 | 20.77 | 476,359 |
| 2024-12-03 | Sethuraman Natarajan (President, Research & Develop.) | Sale | 11,703 | 20.15 | 235,792 |
| 2024-12-02 | Sethuraman Natarajan (President, Research & Develop.) | Sale | 4,088 | 20.26 | 82,835 |
| 2024-12-02 | Wentworth Kory James (Chief Financial Officer) | Sale | 5,000 | 20.00 | 99,980 |
| 2024-12-02 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 5,000 | 2.10 | 10,500 |
| 2024-11-29 | Sethuraman Natarajan (President, Research & Develop.) | Sale | 100 | 20.00 | 2,000 |
| 2024-11-29 | Wentworth Kory James (Chief Financial Officer) | Sale | 1,000 | 19.97 | 19,970 |
| 2024-11-29 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 1,000 | 2.10 | 2,100 |
| 2024-11-13 | Sethuraman Natarajan (President, Research & Develop.) | Sale | 2,700 | 20.04 | 54,108 |
| 2024-11-11 | Sethuraman Natarajan (President, Research & Develop.) | Sale | 1,409 | 20.01 | 28,191 |
| 2024-11-11 | Wentworth Kory James (Chief Financial Officer) | Sale | 8,637 | 19.98 | 172,558 |
| 2024-11-11 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 6,000 | 2.10 | 12,600 |
| 2024-11-06 | Sethuraman Natarajan (President, Research & Develop.) | Sale | 12,299 | 19.01 | 233,840 |
| 2024-11-05 | Sethuraman Natarajan (President, Research & Develop.) | Sale | 5,171 | 18.18 | 94,008 |
| 2024-11-04 | Sethuraman Natarajan (President, Research & Develop.) | Sale | 749 | 18.02 | 13,498 |
| 2024-10-16 | Sethuraman Natarajan (President, Research & Develop.) | Sale | 600 | 18.00 | 10,800 |
| 2024-09-26 | Dowden Nathan J (President & COO) | Sale | 847 | 16.00 | 13,552 |
| 2024-09-09 | Sethuraman Natarajan (Chief Scientific Officer) | Sale | 2,642 | 15.09 | 39,862 |
| 2024-09-09 | Dowden Nathan J (President & COO) | Sale | 1,904 | 15.07 | 28,689 |
| 2024-09-09 | Wentworth Kory James (Chief Financial Officer) | Sale | 3,195 | 14.97 | 47,832 |
| 2024-09-06 | Sethuraman Natarajan (Chief Scientific Officer) | Sale | 600 | 15.24 | 9,141 |
| 2024-09-06 | Dowden Nathan J (President & COO) | Sale | 399 | 15.20 | 6,062 |
| 2024-08-16 | Dowden Nathan J (President & COO) | Sale | 27,097 | 16.48 | 446,531 |
| 2024-08-16 | Dowden Nathan J (President & COO) | Option Ex | 20,000 | 1.74 | 34,800 |
| 2024-07-15 | Sethuraman Natarajan (Chief Scientific Officer) | Sale | 638 | 18.00 | 11,484 |
| 2024-07-15 | Doshi Dipal (CEO) | Sale | 1,600 | 17.81 | 28,497 |
| 2024-07-12 | Sethuraman Natarajan (Chief Scientific Officer) | Sale | 600 | 18.00 | 10,800 |
| 2024-07-12 | Doshi Dipal (CEO) | Sale | 300 | 18.00 | 5,400 |
| 2024-07-08 | Wentworth Kory James (Chief Financial Officer) | Sale | 1,758 | 14.95 | 26,282 |
| 2024-06-13 | Doshi Dipal (CEO) | Sale | 1,000 | 16.17 | 16,174 |
| 2024-06-03 | Kim Peter S (Director) | Option Ex | 11,918 | 6.06 | 72,223 |
| 2024-05-17 | Doshi Dipal (CEO) | Sale | 1,200 | 15.11 | 18,129 |
| 2024-05-16 | Doshi Dipal (CEO) | Sale | 1,800 | 15.00 | 27,000 |
| 2024-05-09 | Kim Peter S (Director) | Buy | 2,200 | 14.25 | 31,341 |
| 2024-05-08 | Kim Peter S (Director) | Buy | 2,276 | 14.04 | 31,964 |
| 2024-04-08 | Kim Peter S (Director) | Buy | 2,600 | 13.57 | 35,289 |
| 2024-03-28 | Kim Peter S (Director) | Buy | 1,512 | 13.75 | 20,794 |
| 2024-03-26 | Kim Peter S (Director) | Buy | 2,750 | 13.64 | 37,510 |
| 2024-03-25 | Kim Peter S (Director) | Buy | 3,180 | 13.36 | 42,472 |
| 2024-03-22 | Kim Peter S (Director) | Buy | 3,118 | 13.76 | 42,900 |
| 2024-03-15 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 9,000 | 2.10 | 18,900 |
| 2024-03-06 | Dowden Nathan J (President & COO) | Sale | 1,826 | 12.32 | 22,498 |
| 2024-03-06 | Wentworth Kory James (Chief Financial Officer) | Sale | 4,086 | 12.31 | 50,286 |
| 2024-01-16 | Doshi Dipal (CEO) | Sale | 1,000 | 15.99 | 15,990 |
| 2023-12-26 | Wentworth Kory James (Chief Financial Officer) | Sale | 94 | 16.67 | 1,566 |
| 2023-12-26 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 94 | 2.10 | 197 |
| 2023-12-22 | Wentworth Kory James (Chief Financial Officer) | Sale | 10,206 | 15.86 | 161,897 |
| 2023-12-22 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 10,206 | 2.10 | 21,432 |
| 2023-12-21 | Wentworth Kory James (Chief Financial Officer) | Sale | 2,200 | 15.07 | 33,154 |
| 2023-12-21 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 2,200 | 2.10 | 4,620 |
| 2023-12-20 | Doshi Dipal (President and CEO) | Sale | 1,000 | 15.00 | 15,000 |
| 2023-11-13 | Doshi Dipal (President and CEO) | Sale | 1,000 | 16.23 | 16,230 |
| 2023-10-17 | Doshi Dipal (President and CEO) | Sale | 1,000 | 15.00 | 15,000 |
| 2023-09-13 | Doshi Dipal (President and CEO) | Sale | 1,000 | 15.00 | 15,000 |
| 2023-09-06 | Dowden Nathan J (Chief Operating Officer) | Sale | 972 | 13.72 | 13,334 |
| 2023-09-06 | Kreher Nerissa (Chief Medical Officer) | Sale | 892 | 13.73 | 12,248 |
| 2023-09-06 | Wentworth Kory James (Chief Financial Officer) | Sale | 950 | 13.74 | 13,053 |
| 2023-08-14 | Doshi Dipal (President and CEO) | Sale | 1,000 | 15.67 | 15,671 |
| 2023-08-04 | Kreher Nerissa (Chief Medical Officer) | Sale | 6,898 | 14.14 | 97,523 |
| 2023-08-04 | Kreher Nerissa (Chief Medical Officer) | Option Ex | 6,898 | 2.10 | 14,485 |
| 2023-08-03 | Kreher Nerissa (Chief Medical Officer) | Sale | 9,464 | 14.74 | 139,527 |
| 2023-08-03 | Kreher Nerissa (Chief Medical Officer) | Option Ex | 9,464 | 2.10 | 19,874 |
| 2023-08-02 | Kreher Nerissa (Chief Medical Officer) | Sale | 10,348 | 15.97 | 165,288 |
| 2023-08-02 | Kreher Nerissa (Chief Medical Officer) | Option Ex | 10,348 | 2.10 | 21,730 |
| 2023-07-11 | Sethuraman Natarajan (Chief Scientific Officer) | Sale | 14,852 | 18.04 | 267,915 |
| 2023-07-11 | Dowden Nathan J (Chief Operating Officer) | Sale | 3,897 | 18.05 | 70,333 |
| 2023-07-11 | Wentworth Kory James (Chief Financial Officer) | Sale | 3,884 | 18.00 | 69,904 |
| 2023-07-11 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 3,884 | 2.10 | 8,156 |
| 2023-07-10 | Sethuraman Natarajan (Chief Scientific Officer) | Sale | 3,026 | 18.00 | 54,474 |
| 2023-07-10 | Dowden Nathan J (Chief Operating Officer) | Sale | 3,200 | 18.00 | 57,606 |
| 2023-07-10 | Wentworth Kory James (Chief Financial Officer) | Sale | 6,116 | 17.98 | 109,959 |
| 2023-07-10 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 6,116 | 2.10 | 12,843 |
| 2023-06-29 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 8,790 | 2.10 | 18,459 |
| 2023-06-22 | Dowden Nathan J (Chief Operating Officer) | Sale | 7,097 | 16.02 | 113,701 |
| 2023-06-21 | Wentworth Kory James (Chief Financial Officer) | Sale | 17,500 | 15.01 | 262,605 |
| 2023-06-21 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 17,500 | 2.10 | 36,750 |
| 2023-06-20 | Dowden Nathan J (Chief Operating Officer) | Sale | 8,885 | 14.94 | 132,706 |
| 2023-04-27 | Doshi Dipal (President and CEO) | Sale | 2,000 | 13.71 | 27,422 |
| 2023-04-17 | Sethuraman Natarajan (Chief Scientific Officer) | Sale | 3,961 | 18.00 | 71,317 |
| 2023-04-17 | Doshi Dipal (President and CEO) | Sale | 2,092 | 18.01 | 37,674 |
| 2023-03-27 | Doshi Dipal (President and CEO) | Sale | 2,000 | 15.07 | 30,140 |
| 2023-03-02 | Kreher Nerissa (Chief Medical Officer) | Sale | 1,641 | 10.86 | 17,816 |
| 2023-03-02 | Wentworth Kory James (Chief Financial Officer) | Sale | 1,747 | 10.85 | 18,946 |
| 2023-02-28 | Doshi Dipal (President and CEO) | Sale | 2,000 | 12.00 | 24,000 |
| 2023-01-27 | Doshi Dipal (President and CEO) | Sale | 2,000 | 12.00 | 24,002 |
| 2022-11-28 | Doshi Dipal (President and CEO) | Sale | 2,000 | 13.91 | 27,826 |
| 2022-11-16 | Wentworth Kory James (Chief Financial Officer) | Sale | 200 | 18.10 | 3,620 |
| 2022-11-16 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 200 | 2.10 | 420 |
| 2022-10-27 | Doshi Dipal (President and CEO) | Sale | 2,000 | 21.66 | 43,326 |
| 2022-10-26 | Kreher Nerissa (Chief Medical Officer) | Sale | 4,960 | 21.61 | 107,190 |
| 2022-10-26 | Kreher Nerissa (Chief Medical Officer) | Option Ex | 4,960 | 2.10 | 10,416 |
| 2022-10-25 | Dowden Nathan J (Chief Operating Officer) | Sale | 9,348 | 20.98 | 196,083 |
| 2022-10-25 | Kreher Nerissa (Chief Medical Officer) | Sale | 8,040 | 21.36 | 171,734 |
| 2022-10-25 | Kreher Nerissa (Chief Medical Officer) | Option Ex | 8,040 | 2.10 | 16,884 |
| 2022-10-25 | Doshi Dipal (President and CEO) | Sale | 12,061 | 20.76 | 250,338 |
| 2022-10-24 | Dowden Nathan J (Chief Operating Officer) | Sale | 2,404 | 19.27 | 46,325 |
| 2022-10-24 | Doshi Dipal (President and CEO) | Sale | 2,342 | 19.27 | 45,137 |
| 2022-10-21 | Dowden Nathan J (Chief Operating Officer) | Sale | 2,771 | 18.29 | 50,667 |
| 2022-10-21 | Doshi Dipal (President and CEO) | Sale | 2,786 | 18.28 | 50,916 |
| 2022-10-20 | Dowden Nathan J (Chief Operating Officer) | Sale | 905 | 18.07 | 16,356 |
| 2022-10-20 | Doshi Dipal (President and CEO) | Sale | 811 | 18.01 | 14,606 |
| 2022-09-28 | Kreher Nerissa (Chief Medical Officer) | Sale | 3,122 | 15.25 | 47,610 |
| 2022-09-28 | Kreher Nerissa (Chief Medical Officer) | Option Ex | 3,122 | 2.10 | 6,556 |
| 2022-09-28 | Doshi Dipal (President and CEO) | Sale | 3,085 | 15.23 | 46,996 |
| 2022-09-27 | Kreher Nerissa (Chief Medical Officer) | Sale | 2,403 | 15.31 | 36,789 |
| 2022-09-27 | Kreher Nerissa (Chief Medical Officer) | Option Ex | 2,403 | 2.10 | 5,046 |
| 2022-09-27 | Doshi Dipal (President and CEO) | Sale | 4,419 | 15.43 | 68,194 |
| 2022-09-26 | Dowden Nathan J (Chief Operating Officer) | Sale | 1,544 | 15.78 | 24,370 |
| 2022-09-26 | Kreher Nerissa (Chief Medical Officer) | Sale | 3,068 | 15.78 | 48,397 |
| 2022-09-26 | Kreher Nerissa (Chief Medical Officer) | Option Ex | 3,068 | 2.10 | 6,442 |
| 2022-09-26 | Doshi Dipal (President and CEO) | Sale | 3,083 | 15.76 | 48,588 |
| 2022-09-23 | Dowden Nathan J (Chief Operating Officer) | Sale | 1,018 | 15.07 | 15,340 |
| 2022-09-23 | Kreher Nerissa (Chief Medical Officer) | Sale | 939 | 15.09 | 14,166 |
| 2022-09-23 | Kreher Nerissa (Chief Medical Officer) | Option Ex | 939 | 2.10 | 1,971 |
| 2022-09-23 | Doshi Dipal (President and CEO) | Sale | 1,023 | 15.07 | 15,412 |
| 2022-09-21 | Dowden Nathan J (Chief Operating Officer) | Sale | 3,275 | 15.13 | 49,537 |
| 2022-09-21 | Kreher Nerissa (Chief Medical Officer) | Sale | 3,341 | 15.08 | 50,392 |
| 2022-09-21 | Kreher Nerissa (Chief Medical Officer) | Option Ex | 3,341 | 2.10 | 7,016 |
| 2022-09-21 | Doshi Dipal (President and CEO) | Sale | 3,402 | 15.12 | 51,424 |
| 2022-09-15 | Dowden Nathan J (Chief Operating Officer) | Sale | 500 | 15.01 | 7,505 |
| 2022-09-15 | Kreher Nerissa (Chief Medical Officer) | Sale | 530 | 15.01 | 7,955 |
| 2022-09-15 | Kreher Nerissa (Chief Medical Officer) | Option Ex | 530 | 2.10 | 1,110 |
| 2022-09-15 | Doshi Dipal (President and CEO) | Sale | 1,000 | 15.04 | 15,040 |
| 2022-08-31 | Doshi Dipal (President and CEO) | Sale | 171 | 12.00 | 2,052 |
| 2022-08-30 | Doshi Dipal (President and CEO) | Sale | 190 | 12.00 | 2,280 |
| 2022-08-29 | Doshi Dipal (President and CEO) | Sale | 1,639 | 13.36 | 21,892 |
| 2022-08-23 | Wentworth Kory James (Chief Financial Officer) | Sale | 2,909 | 13.09 | 38,078 |
| 2022-08-23 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 1,403 | 2.10 | 2,946 |
| 2022-08-22 | Wentworth Kory James (Chief Financial Officer) | Sale | 217 | 13.01 | 2,822 |
| 2022-08-22 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 117 | 2.10 | 245 |
| 2022-08-19 | Wentworth Kory James (Chief Financial Officer) | Sale | 8,529 | 13.08 | 111,533 |
| 2022-08-19 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 4,452 | 2.10 | 9,349 |
| 2022-08-18 | Wentworth Kory James (Chief Financial Officer) | Sale | 200 | 13.00 | 2,600 |
| 2022-08-18 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 100 | 2.10 | 210 |
| 2022-08-17 | Wentworth Kory James (Chief Financial Officer) | Sale | 200 | 13.07 | 2,614 |
| 2022-08-17 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 100 | 2.10 | 210 |
| 2022-08-16 | Wentworth Kory James (Chief Financial Officer) | Sale | 200 | 13.00 | 2,600 |
| 2022-08-16 | Wentworth Kory James (Chief Financial Officer) | Option Ex | 100 | 2.10 | 210 |
| 2022-07-27 | Doshi Dipal (President and CEO) | Sale | 2,000 | 12.00 | 24,000 |
| 2022-06-27 | Dowden Nathan J (Chief Operating Officer) | Sale | 7,714 | 13.00 | 100,282 |
| 2022-06-27 | Doshi Dipal (President and CEO) | Sale | 4,000 | 12.00 | 48,000 |
| 2022-06-06 | Baker Bros. Advisors (gp) Llc (10% Owner) | Buy | 38,304 | 6.39 | 244,685 |
| 2022-06-02 | Baker Bros. Advisors (gp) Llc (10% Owner) | Buy | 2,643 | 5.82 | 15,382 |
| 2022-05-24 | Baker Bros. Advisors (gp) Llc (10% Owner) | Buy | 23,823 | 5.84 | 139,031 |
| 2022-05-23 | Baker Bros. Advisors (gp) Llc (10% Owner) | Buy | 7,837 | 5.99 | 46,920 |
| 2022-05-20 | Baker Bros. Advisors (gp) Llc (10% Owner) | Buy | 16,849 | 5.84 | 98,431 |
| 2022-05-18 | Baker Bros. Advisors (gp) Llc (10% Owner) | Buy | 34,433 | 5.96 | 205,186 |
| 2022-05-17 | Baker Bros. Advisors (gp) Llc (10% Owner) | Buy | 18,511 | 6.13 | 113,472 |
| 2022-05-16 | Baker Bros. Advisors (gp) Llc (10% Owner) | Buy | 19,000 | 5.83 | 110,694 |
| 2022-01-13 | Doshi Dipal (President and CEO) | Option Ex | 10,000 | 1.74 | 17,400 |
| 2022-01-12 | Crowley John F | Buy | 5,000 | 9.71 | 48,575 |
| 2021-12-29 | Kreher Nerissa (Chief Medical Officer) | Option Ex | 5,200 | 2.10 | 10,920 |
| 2021-11-02 | Redmile Biopharma Investments Iii, L.p. | Buy | 1,000,000 | 20.00 | 20,000,000 |
| 2021-11-02 | Mpm Bioventures 2018 Gp Llc (10% Owner) | Buy | 100,000 | 20.00 | 2,000,000 |
| 2021-11-02 | Mpm Asset Management Investors Bv2018 Llc (10% Owner) | Buy | 100,000 | 20.00 | 2,000,000 |
| 2021-11-02 | Parmar Kush | Buy | 250,000 | 20.00 | 5,000,000 |
| 2021-11-02 | Schwab Andrew J. (10% Owner) | Buy | 250,000 | 20.00 | 5,000,000 |
| 2021-11-02 | Foley Todd (Director) | Buy | 100,000 | 20.00 | 2,000,000 |
Insider trading activities including stock purchases, stock sales, and option exercises of TRDA listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Entrada Therapeutics, Inc. (symbol TRDA, CIK number 1689375) see the Securities and Exchange Commission (SEC) website.